華仁藥業(300110.SZ):一季度淨利預增0%-20%
格隆匯3月30日丨華仁藥業(300110.SZ)披露2020年第一季度業績預告,公司預計2020年1-3月實現歸屬於上市公司股東的淨利潤490.79萬元-588.95萬元,同比增長0%-20%。業績變動原因説明:
1、2020年第一季度,受新型冠狀病毒肺炎疫情影響,短期內物流、人員返崗受阻,醫院就診人數下降,對原料採購、藥品生產、市場銷售造成一定影響,公司輸液產品銷量出現一定的下降。
2、報告期內,公司積極佈局新增業務板塊,新業務貢獻部分利潤。
3、公司2019年歸還大額銀行借款,財務費用較去年同期下降。
4、報告期內公司非經常損益約為380萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.